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Abstract: 
Purpose  
This study aimed to develop hypotheses to explain the increasing tramadol 
utilisation, evaluate the impact of tramadol classification and explore the 
trend between tramadol utilisation and related deaths in the United 
Kingdom.  
 
Methods  
This cross-sectional study used individual patient data, the Clinical Practice 
Research Datalink from 1993 to 2015, to calculate monthly Defined Daily 
Dose (DDD)/1000 registrants, monthly prevalence and incidence of 
tramadol users, annual supply days and mean daily dose of tramadol. 
Aggregated-level national statistics and prescribing reimbursement data 
from 2004 to 2015 were also used to quantify annual and monthly 
tramadol DDD/1000 inhabitants and rate of tramadol-related deaths in 
England and Wales. Interrupted time-series analysis was used to evaluate 
the impact of tramadol classification in June 2014.  
 
Results  
Prevalence of tramadol users increased from 23 to 97.6/10000 registrants 
from 2000 to 2015. Both annual dose and annual supply days of existing 
tramadol users were higher than new users. Level and trend of monthly 
utilisation (β2: -12.9, β3: -1.6) and prevalence of tramadol users (β2: -
6.4, β3: -0.37) significantly reduced after classification. Both annual 
tramadol utilisation and rate of tramadol-related deaths increased before 
tramadol classification, and decreased thereafter.  
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Conclusions  
Increasing tramadol utilisation was influenced by the increase in 
prevalence and incidence of tramadol users, mean daily dose and day of 
supply. Prevalence of tramadol users, tramadol utilisation and reported 
deaths declined after tramadol classification. Future studies need to 
evaluate the influencing factors to ensure the safety of long-term tramadol 
use.  
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Abstract 35 
Purpose 36 
This study aimed to develop hypotheses to explain the increasing tramadol utilisation, 37 
evaluate the impact of tramadol classification and explore the trend between tramadol 38 
utilisation and related deaths in the United Kingdom. 39 
Methods 40 
This cross-sectional study used individual patient data, the Clinical Practice Research 41 
Datalink from 1993 to 2015, to calculate monthly Defined Daily Dose (DDD)/1000 42 
registrants, monthly prevalence and incidence of tramadol users, annual supply days 43 
and mean daily dose of tramadol. Aggregated-level national statistics and prescribing 44 
reimbursement data from 2004 to 2015 were also used to quantify annual and 45 
monthly tramadol DDD/1000 inhabitants and rate of tramadol-related deaths in 46 
England and Wales. Interrupted time-series analysis was used to evaluate the impact 47 
of tramadol classification in June 2014. 48 
Results 49 
Prevalence of tramadol users increased from 23 to 97.6/10000 registrants from 2000 50 
to 2015. Both annual dose and annual supply days of existing tramadol users were 51 
higher than new users. Level and trend of monthly utilisation (β2: -12.9, β3: -1.6) and 52 
prevalence of tramadol users (β2: -6.4, β3: -0.37) significantly reduced after 53 
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classification. Both annual tramadol utilisation and rate of tramadol-related deaths 54 
increased before tramadol classification, and decreased thereafter. 55 
Conclusions 56 
Increasing tramadol utilisation was influenced by the increase in prevalence and 57 
incidence of tramadol users, mean daily dose and day of supply. Prevalence of 58 
tramadol users, tramadol utilisation and reported deaths declined after tramadol 59 
classification. Future studies need to evaluate the influencing factors to ensure the 60 
safety of long-term tramadol use.61 
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5 
Introduction 62 
Tramadol is indicated for moderate to severe pain in the United Kingdom (UK). 63 
In the past decade, the utilisation of tramadol has consistently increased in 64 
many countries, including the United States (US), Germany1 as well as the 65 
UK2. According to the UK National Health Service (NHS) Business Services 66 
Authority (BSA), the annual tramadol utilisation in England increased from 5.9 67 
to 11.1 million Defined Daily Doses (DDD) between 2005 and 20122; 68 
coincidently, there was a marked increase in the number of tramadol-related 69 
deaths during the same period. 70 
 71 
In the US, prolonged opioid use for persistent pain has been identified as the 72 
main reason for increasing opioid utilisation,3 although several clinical 73 
guidelines4-6 suggest the long-term opioid use for chronic non-cancer pain 74 
(CNCP) remains controversial.7, 8 However, the reasons attributable to the 75 
increasing opioid utilisation, such as tramadol have not been investigated in 76 
the UK. 77 
 78 
Currently, there is no direct evidence to infer the relationship between 79 
increasing tramadol utilisation and related mortality in the UK. At the 80 
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population level, the NHS BSA only presented tramadol utilisation without 81 
adjusting for population size, and tramadol utilisation in Wales was not 82 
included in the report;2 but the published mortality figures from the Office for 83 
National Statistics (ONS) covered both England and Wales.9 Consequently, 84 
the correlation between tramadol utilisation and tramadol-related deaths has 85 
not been established.2 86 
 87 
Due to the concerns about safety and potential risk of misuse, tramadol was 88 
classified as a Schedule 3 Controlled Substance in June 2014 in the U.K.2 89 
Thereafter, tramadol prescribing needs to follow stricter prescription 90 
requirements with clear defined dose and the maximum supply days should 91 
not exceed 30 days2. For such a medication with high usage and potential 92 
harm, the effectiveness of policy intervention on utilisation and 93 
tramadol-related mortality is an important public health issue. However, the 94 
effect of tramadol classification has not been explored. 95 
 96 
Therefore, this study aimed to develop hypotheses to explain the increasing 97 
tramadol utilisation and evaluate policy changes in the UK. The objectives 98 
were to (1) identify potential reasons for increasing tramadol utilisation from 99 
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7 
individual utilisation patterns; (2) evaluate the impact of tramadol classification 100 
on prevalence of tramadol users and tramadol utilisation; and (3) explore the 101 
trend between tramadol utilisation and tramadol-related deaths.102 
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Methods 103 
Study design and data source 104 
This cross-sectional study used several data sources which cover information from 105 
different geographical region and time frames, including aggregated-level and 106 
publically available data from the UK government sources as well as individual patient 107 
data (IPD) from a UK primary care database to address multiple research questions 108 
and compensate limitation of each database (Table 1). 109 
 110 
To explore potential reasons for the increasing tramadol utilisation from individual 111 
utilisation patterns, validate findings about the impact of tramadol classification on 112 
monthly tramadol utilisation from aggregate-level data and evaluate the impact of 113 
tramadol classification on prevalence of tramadol users and tramadol utilisation, a UK 114 
primary care database, the Clinical Practice Research Datalink (CPRD) from January 115 
1993 to December 2015 was used after receiving approval from the Independent 116 
Scientific Advisory Committee of the Medicines and Healthcare Products Regulatory 117 
Agency (Protocol number: 12_007RA). 118 
 119 
CPRD is the largest verified primary care database of anonymised clinical records in 120 
the UK. IPD in CPRD were prospectively collected from general practitioners’ daily 121 
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9 
records and it represents about 8.3% of the UK population up to March 2016.10-12 The 122 
population is representative of the UK general population in terms of the age and 123 
gender distribution, and hence, CPRD has been widely used in drug utilisation 124 
research in UK primary care.13, 14  125 
 126 
Monthly practice-level dispensing data from October 2010 to September 2015 was 127 
used as the primary data source to evaluate the impact of tramadol classification on 128 
monthly tramadol utilisation in England.15 To explore the correlation between annual 129 
tramadol utilisation and tramadol-related deaths between 2004 and 2015, this study 130 
used mortality data which is originally recorded by the International Classification of 131 
Diseases-the tenth version (ICD-10) diagnosis codes9, annual aggregated-level 132 
dispensing data from Prescription Cost Analysis (PCA) in England16 and Wales17 and 133 
the annual number of mid-year population estimates from the ONS18. Those 134 
aggregate-level data are publically available and use requires no ethical review. 135 
 136 
<Insert Table 1> 137 
 138 
Study population 139 
For the IPD analysis, adult CPRD registrants (age >18 years) prescribed tramadol 140 
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10 
between January 2000 and December 2015 were included. For monthly 141 
practice-level dispensing data, practices which issued any tramadol prescriptions 142 
between October 2010 and September 2015 in England were included. 143 
 144 
Outcomes measured using aggregated-level data 145 
The annual number of tramadol-related deaths/100000 inhabitants and annual and 146 
monthly DDDs of dispensed tramadol/1000 inhabitants were measured in 147 
aggregated-level statistics and datasets. The number of tramadol related deaths was 148 
directly extracted from government reports.9 The annual quantity of tramadol 149 
preparations reported in the PCA was used to calculate the annual number of DDDs 150 
dispensed in England16 and Wales17. While the quantity of tramadol preparations 151 
extracted from monthly practice-level dispensing data were used to calculate the 152 
monthly number of DDDs dispensed in England.15  153 
 154 
The annual number of tramadol-related deaths was divided by the mid-year number 155 
of population in England and Wales and then multiplied by 100000 to calculate the 156 
annual number of tramadol-related deaths/100000 inhabitants. The total dose of each 157 
tramadol preparation was calculated by multiplying strength (in milligrams) and 158 
quantity, and then summed in annual or monthly basis, and then divided by 300 (as 159 
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11 
defined by the World Health Organisation19) to calculate the number of DDDs of 160 
tramadol. The annual or monthly DDD was adjusted by the mid-year number of 161 
population18 to derive the annual or monthly number of DDDs of dispensed 162 
tramadol/1000 inhabitants. 163 
 164 
Outcomes measured using individual patient data 165 
The monthly prevalence and incidence of tramadol users/10000 registrants, monthly 166 
DDDs/1000 registrants and annual supply days and mean daily dose for each 167 
tramadol user were measured by using tramadol prescription records form CPRD. 168 
 169 
Adult patients who received their first tramadol prescription during the study period 170 
were identified as new tramadol users in that calendar year, and if the patients 171 
received tramadol in the subsequence years, they will be classified as existing users 172 
in the subsequence years. The number of new and existing tramadol users were 173 
calculated in each calendar month, and adjusted by the total number of active 174 
patients in the CPRD to derive the monthly incidence and prevalence of tramadol 175 
users/10000 registrants. 176 
 177 
The total dose of each tramadol prescription was calculated by multiplying strength 178 
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12 
and quantity, and then converted to the monthly number of DDDs; which was further 179 
adjusted by the number of active patients in the particular calendar month to calculate 180 
the monthly number of DDDs of tramadol/1000 registrants. 181 
 182 
For each tramadol prescription, the dose was divided by numerical daily dose 183 
(recorded by physicians and available in the CPRD therapy file) to derive the number 184 
of supply days. If the interval between two consecutive prescriptions was shorter than 185 
the supply day of the anterior prescription, then the supply day was replaced by 186 
interval between the two prescriptions.  187 
 188 
For each patient, the total doses of tramadol prescriptions and annual number of 189 
supply days were summed in each calendar year. If the annual number of supply 190 
days was more than 365 days, then it was capped to 365 days. The annual dose was 191 
divided by annual number of supply days to derive the annual mean daily dose in 192 
particular calendar year. 193 
 194 
Data analysis 195 
Descriptive statistics were used to report annual dose and number of supply days. 196 
The trend of (1) monthly incidence and prevalence of tramadol users from January 197 
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13 
2000 to December 2015; (2) annual mean daily dose stratified by new and existing 198 
users; (3) annual number of DDDs of dispensed tramadol/1000 inhabitants and the 199 
rate of tramadol-related deaths in England and Wales from 2004 to 2015 were 200 
reported graphically. Cross-correlation between the two time-series, i.e. annual 201 
number of tramadol-related deaths/100000 inhabitants and annual number of DDDs 202 
of dispensed tramadol/1000 inhabitants, was investigated at no lag time effect and 203 
presented as cross-correlation coefficient (ranged from -1 to 1). 204 
 205 
Interrupted time-series analysis (ITSA)20 was used to evaluate the impact of tramadol 206 
classification in June 2014 on the levels and trends of two series between October 207 
2010 and September 2015: (1) monthly prevalence and incidence of tramadol users 208 
estimated from CPRD; (2) monthly DDD/1000 registrants estimated from both 209 
monthly practice-level dispensing data and CPRD. I  CPRD, monthly DDD/1000 210 
registrants was further stratified by new and existing users to identify the impact of 211 
tramadol classification on different patient groups. 212 
 213 
The Durbin Watson test was used to test first-order autocorrelation in each time 214 
series, as no first-order autocorrelation was found21, and hence auto-regressive 215 
integrated moving-average (ARIMA) model was not applied in the ITSA22. In the 216 
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14 
regimented regression model, baseline trend before classification (β1), change in the 217 
level (β2) and change in trend after classification (β3) were tested and reported for 218 
each time series.  Additional time points in the policy development were tested in 219 
sensitivity analysis (Appendix 1). All analysis was performed using STATA 14 220 
(Stata-Corp, Texas, USA, 2015).  221 
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15 
Results 222 
Trend of prevalence and incidence of tramadol users from 2000 to 2015 223 
The IPD extracted from CPRD showed that the monthly prevalence and incidence of 224 
tramadol users increased from 23 to 99.3/10000 registrants and 4.1 to 7.7/10000 225 
registrants respectively between January 2000 and May 2014 (Figure 1). 226 
 227 
<Insert Figure 1> 228 
 229 
Annual dose, supply days and mean daily dose from 2000 to 2015 230 
For all adult tramadol users in CPRD, most tramadol prescriptions were issued for 231 
existing tramadol users. In 2000, 69.2% of the annual tramadol dose was prescribed 232 
to existing tramadol users, and this proportion increased to 91.4% in 2015 (Appendix 233 
2). In addition, between 2000 and 2015, the annual dose per existing tramadol user in 234 
each calendar year (range: 37910.8 to 40218.2 mg) was consistently higher than the 235 
annual dose per new users (range: 9717.8 to 11642.6 mg). Furthermore, the annual 236 
supply days per existing tramadol users in each calendar year (range: 134.3 to 150.7 237 
days) was consistently higher than new users (range: 35.7 to 47.9 days) (Appendix 238 
3). 239 
 240 
From 2000 to 2013, the annual mean daily tramadol dose increased in both existing 241 
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16 
and new users. After 2007, new users had greater annual mean daily dose than 242 
existing users, however, since tramadol classification, the annual mean daily dose of 243 
new users decreased in 2014 and 2015 (Figure 2). 244 
 245 
<Insert Figure 2> 246 
 247 
Impact of tramadol classification on monthly tramadol utilisation 248 
Tramadol classification had similar impacts on its utilisation in the results of ITSA 249 
using aggregated-level data and IPD. In the monthly practice-level dispensing data, 250 
the ITSA revealed that the level (β2: -12.9, p=0.017) and the trend (β3: -1.6, p=0.002) 251 
of monthly tramadol utilisation significantly decreased after tramadol classification, 252 
despite there was a significant increase in the baseline trend (β1: 0.79, p<0.001) 253 
before tramadol classification (Figure 3).  254 
 255 
<Insert Figure 3> 256 
 257 
Similarly, the IPD from CPRD showed a significant increase trend (β1: 0.56, p<0.001) 258 
before tramadol classification, and the level significantly reduced at the launch of 259 
classification (β2: -16.3, p=0.021) but there was no significant change in the trend of 260 
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17 
tramadol utilisation after classification. 261 
 262 
When stratifying monthly tramadol utilisation into existing and new tramadol users, 263 
before the classification, the trend significantly increased in existing users (β1: 0.63, 264 
p<0.001) (Figure 4) but decreased in new users (β1: -0.07, p<0.001) (Figure 5). After 265 
the launch of tramadol classification, the level significantly decreased in both existing 266 
users (β2: -13.8, p=0.041) and new (β2: -2.6, p<0.001) users. However, there was no 267 
significant change in the trend of tramadol utilisation for both existing and new users 268 
after tramadol classification.  269 
 270 
<Insert Figure 4> 271 
 272 
<Insert Figure 5> 273 
 274 
Impact of tramadol classification on monthly prevalence and incidence of 275 
tramadol users 276 
In addition to the decrease in monthly tramadol utilisation, tramadol classification also 277 
decreased the prevalence of tramadol users. In the IPD from CPRD, the baseline 278 
trend significantly increased in prevalence (β1: 0.21, p<0.001) but decreased in 279 
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18 
incidence (β1: -0.04, p<0.001) of tramadol users between October 2010 and May 280 
2014. The level of both prevalence (β2: -6.4, p=0.001) and incidence (β2: -1.7, 281 
p<0.001) decreased significantly after the launch of tramadol classification. However, 282 
only the trend of prevalence decreased significantly (β3: -0.37, p=0.028) and there 283 
was no significant change in the trend of incidence (Figure 1). All sensitivity analysis 284 
models found that other intervention time points had no significant effect on tramadol 285 
utilisation, prevalence and incidence. 286 
 287 
Trend of annual tramadol utilisation and tramadol-related deaths from 2004 to 288 
2014 289 
Before tramadol classification, the annual tramadol utilisation summarised in PCA in 290 
England and Wales increased from 1190.4 to 2714.7 DDDs/1000 inhabitants during 291 
2004 and 2013; meanwhile the number of tramadol-related deaths/100000 292 
inhabitants increased from 0.08 in 2004 to 0.42 in 2014 (Figure 6). After tramadol 293 
classification, tramadol annual utilisation decreased, and the number of 294 
tramadol-related deaths/100000 inhabitants decreased to 0.36 in 2015. A strong 295 
positive correlation was found between tramadol annual utilisation and related deaths 296 
(cross-correlation coefficient=0.9090).  297 
 298 
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<Insert Figure 6> 299 
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Discussion 300 
This study found monthly tramadol utilisation consistently increased before tramadol 301 
classification and the increasing trend did not act as a substitution of other more 302 
potent opioids because the utilisation of all strong opioids and codeine consistently 303 
increased since 2004.2 Furthermore, the withdrawal of co-proxamol in 2005 did not 304 
change the increasing trend of tramadol utilisation and tramadol-related death from 305 
2000.23 306 
 307 
From the IPD, the monthly incidence of tramadol users doubled and the monthly 308 
prevalence increased four-fold. The mean daily dose of tramadol prescriptions 309 
increased and more than 70% of tramadol users were existing users who had greater 310 
number of supply days than new users. Therefore, the increasing prevalence and 311 
incidence of tramadol users, higher mean daily dose and the prolonged use of 312 
tramadol were the main causes of increasing tramadol utilisation over time. 313 
 314 
From the monthly practice-level dispensing data, the monthly tramadol utilisation 315 
decreased after tramadol classification. Once tramadol users were stratified into new 316 
and existing users in the IPD, the level of tramadol utilisation and the prevalence of 317 
tramadol users decreased after classification, but only the trend of prevalence of 318 
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tramadol users changed significantly after June 2014. 319 
 320 
Overall, a similar trend between annual tramadol utilisation and the rate of 321 
tramadol-related deaths was found, which is consistent with government 322 
publications.2, 9 In short, after the launch of tramadol classification, monthly 323 
prevalence and incidence, overall tramadol utilisation and the number of 324 
tramadol-related deaths decreased reversing the upward trend from 2004. 325 
 326 
The increasing tramadol utilisation may be attributed to long-term opioid utilisation 327 
which is commonly observed in patients with CNCP.3 In the UK, higher does and 328 
prolonged use of strong opioids was related to increasing demands for pain relief in 329 
CNCP.24 In addition, a cross-sectional study conducted in Germany found that higher 330 
tramadol utilisation was associated with CNCP diagnosis.1 However, similar to other 331 
opioids, there is currently no robust evidence to support the clinical effectiveness of 332 
prolonged tramadol utilisation for CNCP.25-28 Moreover, evidence from post-mortem 333 
toxicological analysis in the UK suggests that tramadol-related deaths were more 334 
related to persistent tramadol users.29-31 335 
 336 
Nevertheless, the ITSA found tramadol classification did not change the increasing 337 
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trend of tramadol utilisation in existing tramadol users who had greater number of 338 
supply days. In addition, the proportion of tramadol-related deaths in all opioid-related 339 
deaths (10.5%) was still higher than codeine-related deaths (6.4%) in 2015, despite 340 
more prescriptions for codeine being dispensed.9 341 
 342 
Although indicators to monitor tramadol related deaths are needed, as tramadol has 343 
been considered relatively safe comparing with other strong opioids8, only one of the 344 
previous nested case-control studies which assessed the association between risk 345 
factors and opioid-related deaths included tramadol.7, 8, 32, 33 Furthermore, tramadol 346 
related deaths involved multiple risk factors29-31, but there is currently no applicable 347 
indicators to monitor tramadol utilisation and related deaths. 348 
 349 
In the ITSA, the decreased trend in monthly tramadol utilisation was found in the 350 
aggregated monthly practice-level dispensing data but not in IPD. Some reasons 351 
might explain the different results derived from the two data sources. First, CPRD 352 
contains prescribing records from general practices, but NHS Digital data included 353 
community dispensing records, and prescriptions are not necessary always been 354 
dispensed. Second, CPRD collects prescription records from selected practices 355 
across the UK whereas NHS Digital obtains all dispensing data in England. There 356 
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might be some variations in patients’ characteristics and prescribers’ clinical decision 357 
making between practices in CPRD and NHS Digital dispensing data. In fact, 358 
geographic variation in opioid prescribing has been found in the USA and 359 
Australia34-36, and it was possible that the interpretation and application of policy 360 
varied between practices in different regions. 361 
 362 
This is the first study to identify the influence of tramadol classification on its utilisation 363 
in the UK. To fully explore tramadol utilisation in the past 15 years, several national 364 
statistics and datasets as well as CPRD were used to compensate the limitations of 365 
each database. We used DDDs to quantify tramadol utilisation which is easy to 366 
compare with previous studies and understand the clinical implication as it can be 367 
converted into oral morphine equivalent dose by multiplying the potency ratio.37 368 
Furthermore, to establish hypotheses for further analysis, potential reasons of 369 
increasing tramadol utilisation and tramadol-related deaths were identified by 370 
measuring both individual and population utilisation. 371 
 372 
There are some limitations to this research. CPRD does not included prescription 373 
records from secondary care and hence may underestimate tramadol utilisation, 374 
especially for acute tramadol use. Tramadol prescriptions outside the study period 375 
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were not included and hence the new users might be over-estimated. Furthermore, 376 
this cross-sectional study aimed to establish potential hypotheses for changes in 377 
tramadol utilisation and deaths, but it was not intended to study the causal 378 
relationship between particular utilisation patterns such as chronic use and changes 379 
in tramadol utilisation. The number of tramadol-related deaths was an aggregated 380 
summary retrieved from government reports and hence characteristics of 381 
tramadol-related fatalities were not available to be explore. 382 
 383 
In conclusion, the prolonged use by existing tramadol users and the increasing 384 
prevalence of tramadol users led to increasing tramadol utilisation over the past 385 
fifteen years in the UK. Although tramadol classification altered tramadol utilisation 386 
and associated deaths, to optimise the use of tramadol in patients with CNCP, future 387 
studies are needed to identify the causal relationship between patient characteristics, 388 
long-term tramadol utilisation and tramadol-related deaths. 389 
  390 
Page 25 of 44
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
25 
References 391 
1. Tholen K and Hoffmann F. High use of tramadol in Germany: an analysis of statutory 392 
health insurance data. Pharmacoepidemiol Drug Saf 2012; 21: 1013-21. DOI: 393 
10.1002/pds.3266 394 
2. Advisory Council on the Misuse of Drugs. Advisory Council on the Misuse of Drugs 395 
consideration of tramadol. February 2013; 396 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/144116/advice397 
-tramadol.pdf [accessed 02 June 2014] 398 
3. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain 399 
conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 400 
2008; 138: 440-9. DOI: 10.1016/j.pain.2008.04.027 401 
4. Hauser W, Bock F, Engeser P, et al. Long-term opioid use in non-cancer pain. Dtsch 402 
Arztebl Int 2014; 111: 732-40. DOI: 10.3238/arztebl.2014.0732 403 
5. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians 404 
(ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 405 
2--guidance. Pain Physician 2012; 15: S67-116.  406 
6. Public Health England. Opioids Aware: A resource for patients and healthcare 407 
professionals to support prescribing of opioid medicines for pain. . 2016; 408 
https://www.fpm.ac.uk/faculty-of-pain-medicine/opioids-aware [accessed 02 October 2016] 409 
7. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing 410 
patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-21. DOI: 411 
10.1001/jama.2011.370. 412 
8. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and 413 
overdose: a cohort study. Ann Intern Med 2010; 152: 85-92. DOI: 414 
10.7326/0003-4819-152-2-201001190-00006 415 
9. Office for National Statistics. Deaths related to drug poisoning in England and Wales, 416 
2015 registrations. 2016; 417 
www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/418 
deathsrelatedtodrugpoisoninginenglandandwales/2015registrations/pdf [accessed 9 419 
September 2016] 420 
10. Clinical Practice Research Datalink. Release notes – CPRD GOLD March 2016. . March 421 
Page 26 of 44
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
26 
2016; https://cprdcw.cprd.com/downloads/FileDownloads.aspx [accessed 23 March 2016] 422 
11. Garcia Rodriguez LA and Perez Gutthann S. Use of the UK General Practice Research 423 
Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-25.  424 
12. Williams T, van Staa T, Puri S, et al. Recent advances in the utility and use of the 425 
General Practice Research Database as an example of a UK Primary Care Data resource. 426 
Ther Adv Drug Saf 2012; 3: 89-99. DOI: 10.1177/2042098611435911 427 
13. Baker A, Chen LC, Elliott RA, et al. The impact of the 'Better Care Better Value' 428 
prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and 429 
angiotensin receptor blockers for treating hypertension in the UK primary care setting: 430 
longitudinal quasi-experimental design. BMC Health Serv Res 2015; 15: 367. DOI: 431 
10.1186/s12913-015-1013-y 432 
14. Taylor A, Chen LC and Smith MD. Adherence to inhaled corticosteroids by asthmatic 433 
patients: measurement and modelling. Int J Clin Pharm 2014; 36: 112-9. DOI: 434 
10.1007/s11096-013-9862-0 435 
15. NHS Digital. General practitioner practice prescribing presentation-level Data. 436 
http://content.digital.nhs.uk/searchcatalogue?topics=1%2fPrescribing%2fPrimary+care+pres437 
cribing&sort=Relevance&size=10&page=1#top [accessed February 2016] 438 
16. NHS Digital. Prescription Cost Analysis England: 2004-2015. 439 
http://content.digital.nhs.uk/searchcatalogue?topics=1%2fPrescribing%2fPrimary+care+pres440 
cribing&sort=Relevance&size=10&page=1#top [accessed March 2016] 441 
17. NHS Wales Shared Services Partnership. Prescription cost analysis: Individual 442 
preparations, 2004-2015. 443 
http://gov.wales/statistics-and-research/prescriptions-dispensed-community/?lang=en 444 
[accessed March 2016] 445 
18. Office for National Statistics. Annual Mid-year Population Estimates: 2004-2015. 446 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populatione447 
stimates [accessed June 2016] 448 
19. World Health Organization. Anatomical therapeutic chemical / defined daily dose index 449 
2016. . March 2016; http://www.whocc.no/atc_ddd_index/ [accessed 10 April 2016 ] 450 
20. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted 451 
time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309. DOI: 452 
10.1046/j.1365-2710.2002.00430.x 453 
Page 27 of 44
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
27 
21. Durbin J and Watson GS. Testing for serial correlation in least squares regression. I. 454 
Biometrika 1950; 37: 409-28.  455 
22. Box EP and Jenkins GM. Time series analysis. London: Holden-Day; 1976.  456 
23. Hawton K, Bergen H, Simkin S, et al. Effect of withdrawal of co-proxamol on prescribing 457 
and deaths from drug poisoning in England and Wales: time series analysis. BMJ 2009; 458 
338:b2270.: 10.1136/bmj.b2270. DOI: 10.1136/bmj.b2270 459 
24. Zin CS, Chen LC and Knaggs RD. Changes in trends and pattern of strong opioid 460 
prescribing in primary care. European Journal of Pain 2014; 18: 1343-51. DOI: 461 
10.1002/j.1532-2149.2014.496.x 462 
25. Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared with placebo or other 463 
treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 464 
1976) 2014; 39: 556-63. DOI: 10.1097/brs.0000000000000249 465 
26. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a 466 
meta-analysis of effectiveness and side effects. CMAJ 2006; 174: 1589-94. DOI: 467 
10.1503/cmaj.051528 468 
27. Hollingshead J, Duhmke RM and Cornblath DR. Tramadol for neuropathic pain. 469 
Cochrane Database Syst Rev 2006; 19. DOI: 10.1002/14651858.CD003726.pub3 470 
28. Mariconti P and Collini R. Tramadol SR in arthrosic and neuropathic pain. Minerva 471 
Anestesiol 2008; 74: 63-8.  472 
29. Hakkinen M, Launiainen T, Vuori E, et al. Comparison of fatal poisonings by prescription 473 
opioids. Forensic Sci Int 2012; 222: 327-31. DOI: 10.1016/j.forsciint.2012.07.011 474 
30. Tjaderborn M, Jonsson AK, Hagg S, et al. Fatal unintentional intoxications with tramadol 475 
during 1995-2005. Forensic Sci Int 2007; 173: 107-11. DOI: 10.1016/j.forsciint.2007.02.007 476 
31. Randall C and Crane J. Tramadol deaths in Northern Ireland: a review of cases from 477 
1996 to 2012. J Forensic Leg Med 2014; 23: 32-6. DOI: 10.1016/j.jflm.2014.01.006 478 
32. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in 479 
patients with nonmalignant pain. Arch Intern Med 2011; 171: 686-91. DOI: 480 
10.1001/archinternmed.2011.117 481 
33. Liang Y and Turner BJ. Assessing risk for drug overdose in a national cohort: role for 482 
both daily and total opioid dose? J Pain 2015; 16: 318-25. DOI: 10.1016/j.jpain.2014.11.007 483 
Page 28 of 44
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
28 
34. McDonald DC and Carlson KE. The ecology of prescription opioid abuse in the USA: 484 
geographic variation in patients' use of multiple prescribers ("doctor shopping"). 485 
Pharmacoepidemiol Drug Saf 2014; 23: 1258-67. DOI: 10.1002/pds.3690 486 
35. Degenhardt L, Gisev N, Cama E, et al. The extent and correlates of community-based 487 
pharmaceutical opioid utilisation in Australia. Pharmacoepidemiology and drug safety 2016; 488 
25: 521-38. DOI: 10.1002/pds.3931 489 
36. McDonald DC, Carlson K and Izrael D. Geographic variation in opioid prescribing in the 490 
U.S. J Pain 2012; 13: 988-96. DOI: 10.1016/j.jpain.2012.07.007 491 
37. Svendsen K, Borchgrevink P, Fredheim O, et al. Choosing the unit of measurement 492 
counts: the use of oral morphine equivalents in studies of opioid consumption is a useful 493 
addition to defined daily doses. Palliat Med 2011; 25: 725-32.  494 
 495 
 496 
  497 
Page 29 of 44
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
29 
Table 
Table 1. A summary of aggregated-level data and individual patient data used in this study  
Data source Dataset Countries and time Extract information Outcome measure 
Aggregated-level statistics and datasets 
ONS Deaths related to drug 
poisoning
9
 
England and Wales, 
2004-2015 
Annual number of 
tramadol-related deaths 
Annual number of tramadol-related deaths/ 
100000 inhabitants 
ONS Annual number of mid-year 
population estimates
18
 
England and Wales, 
2004-2015 
Annual number of mid-year 
population estimates 
Annual and monthly DDD/1000 inhabitants 
Annual number of tramadol-related deaths/ 
100000 inhabitants 
NHS Digital Annual Prescription Cost 
Analysis
16
 
England, 2004-2015 Annual quantity of dispensed 
tramadol preparations 
Annual DDD/1000 inhabitants 
NHS Wales* Annual Prescription Cost 
Analysis
17
  
Wales, 2004-2015 Annual quantity of dispensed 
tramadol preparations 
Annual DDD/1000 inhabitants 
NHS Digital Monthly practice-level 
dispensing data
15
 
England, October 2010 
to September 2015 
Monthly quantity of dispensed 
tramadol preparations 
Monthly DDD/1000 inhabitants 
Individual patient data 
CPRD Therapy file United Kingdom, 
January 1993 to 
December 2015 
Tramadol prescriptions Monthly DDD/1000 registrants 
Monthly incidence and prevalence/10000 
registrants 
Annual supply days and mean daily dose 
Note: ONS: Office for National Statistics, NHS: National Health Service, DDD: Defined Daily Dose, CPRD: Clinical Practice Research Datalink, *NHS Wales Shared Services Partnership 
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Figure 
 
Figure 1. Monthly prevalence and incidence of tramadol users per 10000 registrants between 2000 and 2015 
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Figure 2. Mean daily dose between existing and new tramadol users
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Figure 3. Monthly tramadol utilisation in England between October 2010 and September 2015 in the national 
practice-level dispensing data
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Figure 4. Monthly tramadol utilisation for existing tramadol users between October 2010 and September 2015 in the 
individual patient data retrieved from CPRD
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Figure 5. Monthly tramadol utilisation for new tramadol users between October 2010 and September 2015 in the 
individual patient data retrieved from CPRD
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Figure 6. Annual tramadol utilisation and the number of tramadol-related deaths in England and Wales from 2004 to 
2015 
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Appendices 
Appendix 1. Segmented regression model 
Yt= β0 + β1*time + β2*tramadol classification + β3*time after tramadol classification 
Yt is monthly tramadol utilisation, measured as monthly DDD between October 2010 
and September 2015 from NHS digital practice-level dispensing data and CPRD 
(further stratified by incident and prevalent users). 
time refers to time from October 2010 to September 2015 in a monthly base.  
Tramadol classification is a binary variable and 1 to denote the time from June 
2014. 
Time after tramadol classification refers to time from June 2014 to September 
2015 in a monthly base.  
 
The baseline trend of monthly tramadol utilisation before classification (β1), the 
change in the levels of monthly utilisation (β2) and the change in trend of monthly 
tramadol utilisation after classification (β3) were tested.  
 
Additional time points in the policy development, including the publication of Advisory 
Council on the Misuse of Drugs recommendation (February 2013), commencing 
public consultation about tramadol classification (July 2013) and publishing results of 
the public consultation (March 2014) were included in the segmented regression 
model for sensitivity analysis. 
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Appendix 2. Proportion of the annual tramadol dose prescribed to existing 
users 
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Appendix 3. Annual dose and supply days between existing and new tramadol 
users 
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